Survodutide trial corrects data on liver disease, obesity

A Nature Medicine correction for the SYNCHRONIZE-MASLD trial clarifies the data for Survodutide, a GLP-1/glucagon receptor dual agonist. The study evaluated its efficacy in adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This update is crucial for understanding GLP-1 drug development for non-alcoholic fatty liver conditions.